This medicine is authorised for use in the European Union.


Trepulmix is a medicine for use in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH), a condition linked with high blood pressure in the lungs caused by blood clots. It can be used to improve the capacity for physical activity in patients:

  • who cannot have an operation for treating the condition;
  • whose condition remains or continues to return after an operation to treat it.

CTEPH is rare, and Trepulmix was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 February 2013.

Trepulmix is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but it is used for treating a different form of pulmonary hypertension. The reference medicine for Trepulmix is Remodulin.

Trepulmix contains the active substance treprostinil.

This EPAR was last updated on 22/03/2021

Authorisation details

Product details
Agency product number
Active substance
Treprostinil sodium
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Hypertension, Pulmonary
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
SciPharm Sàrl
Date of issue of marketing authorisation valid throughout the European Union
Contact address

7, Fausermillen
6689 Mertert

Product information

09/03/2021 Trepulmix - EMEA/H/C/005207 - IB/0004


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Treatment of adult patients with WHO Functional Class (FC) III or IV and:

  • inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or
  • persistent or recurrent CTEPH after surgical treatment

to improve exercise capacity.

Assessment history

Related content

How useful was this page?

Add your rating